PL2865391T3 - Sposób wytwarzania liofilizowanej kompozycji farmaceutycznej zawierającej mitomycynę C - Google Patents

Sposób wytwarzania liofilizowanej kompozycji farmaceutycznej zawierającej mitomycynę C

Info

Publication number
PL2865391T3
PL2865391T3 PL13189775T PL13189775T PL2865391T3 PL 2865391 T3 PL2865391 T3 PL 2865391T3 PL 13189775 T PL13189775 T PL 13189775T PL 13189775 T PL13189775 T PL 13189775T PL 2865391 T3 PL2865391 T3 PL 2865391T3
Authority
PL
Poland
Prior art keywords
freeze
producing
pharmaceutical composition
composition containing
dried pharmaceutical
Prior art date
Application number
PL13189775T
Other languages
English (en)
Inventor
Sonja Schuldt-Lieb
Sebastian Bialleck
Ingo Guhde
Michaela Rehberg
Original Assignee
Medac Ges Fuer Klinische Spezialpraeparate Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49515194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2865391(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medac Ges Fuer Klinische Spezialpraeparate Mbh filed Critical Medac Ges Fuer Klinische Spezialpraeparate Mbh
Publication of PL2865391T3 publication Critical patent/PL2865391T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13189775T 2013-10-22 2013-10-22 Sposób wytwarzania liofilizowanej kompozycji farmaceutycznej zawierającej mitomycynę C PL2865391T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13189775.3A EP2865391B1 (de) 2013-10-22 2013-10-22 Verfahren zur Herstellung einer gefriergetrockneten pharmazeutischen Zusammensetzung mit Gehalt an Mitomycin C

Publications (1)

Publication Number Publication Date
PL2865391T3 true PL2865391T3 (pl) 2018-01-31

Family

ID=49515194

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13189775T PL2865391T3 (pl) 2013-10-22 2013-10-22 Sposób wytwarzania liofilizowanej kompozycji farmaceutycznej zawierającej mitomycynę C
PL17188743T PL3272361T3 (pl) 2013-10-22 2013-10-22 Sposób wytwarzania suszonej przez wymrażanie kompozycji farmaceutycznej zawierającej mitomycynę C

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17188743T PL3272361T3 (pl) 2013-10-22 2013-10-22 Sposób wytwarzania suszonej przez wymrażanie kompozycji farmaceutycznej zawierającej mitomycynę C

Country Status (12)

Country Link
US (2) US10688049B2 (pl)
EP (2) EP3272361B1 (pl)
JP (2) JP6461945B2 (pl)
CN (1) CN105744957B (pl)
DK (2) DK3272361T3 (pl)
EA (1) EA036982B1 (pl)
ES (2) ES2648367T3 (pl)
LT (2) LT3272361T (pl)
NO (1) NO2865391T3 (pl)
PL (2) PL2865391T3 (pl)
PT (2) PT2865391T (pl)
WO (1) WO2015059023A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
JP6706988B2 (ja) * 2016-07-20 2020-06-10 日本化薬株式会社 ボルテゾミブを含有する医薬組成物
US20210169871A1 (en) * 2018-04-05 2021-06-10 Tarveda Therapeutics, Inc. Pharmaceutical compositions with reduced tert-butanol levels
CN115279339A (zh) * 2020-01-10 2022-11-01 美国安进公司 稳定的无环糊精的卡非佐米配制品
KR20230118632A (ko) * 2020-12-11 2023-08-11 우로젠 파마 엘티디. 암을 치료하기 위한 물질 및 방법
WO2022133251A1 (en) * 2020-12-17 2022-06-23 Mobius Therapeutics, Llc Injection apparatus and method of use
CN113197870B (zh) * 2021-04-14 2022-07-01 健进制药有限公司 一种注射用丝裂霉素冻干制剂及其制备方法
IN202121042020A (pl) * 2021-09-17 2023-03-24
CN114557970B (zh) * 2022-03-17 2023-03-31 浙江长典药物技术开发有限公司 一种眼用丝裂霉素冻干粉及其制备方法
WO2024079565A1 (en) * 2022-10-12 2024-04-18 Harshal Prabhakar Bhagwatwar Stable mitomycin concentrates
CN118873501A (zh) * 2024-09-03 2024-11-01 浙江长典药物技术开发有限公司 丝裂霉素冻干粉及其制备设备

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB830874A (en) 1957-04-06 1960-03-23 Kyowa Hakko Kogyo Kk A new antibiotic mitomycin c and its production by fermentation
ZA86308B (en) * 1985-02-25 1986-11-26 Bristol Myers Co In-vial deposition of 7-(dimethylaminomethylene)amino-9a-methoxy-mitosane
US5216011A (en) 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
EP0782850A4 (en) * 1994-10-13 1998-03-04 Wakamoto Pharma Co Ltd LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED
DE19957371A1 (de) 1999-11-29 2001-06-13 Medac Klinische Spezialpraep Mitomycin C-Lösung
CN100346784C (zh) 2002-02-22 2007-11-07 先灵公司 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途
CN1712014A (zh) 2004-06-14 2005-12-28 马文·F·刘 甘草甜素的新用途
CN101204382A (zh) 2007-12-13 2008-06-25 厦门大学 植入型抗肿瘤药丝裂霉素双重缓释膜剂及其制备方法
US8168224B2 (en) * 2007-12-19 2012-05-01 Beijing Shengyiyao Science & Technology Development Co., Ltd. Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof

Also Published As

Publication number Publication date
US11766405B2 (en) 2023-09-26
CN105744957A (zh) 2016-07-06
JP2019043969A (ja) 2019-03-22
DK2865391T3 (da) 2017-11-20
EP2865391A1 (de) 2015-04-29
US10688049B2 (en) 2020-06-23
JP2016534060A (ja) 2016-11-04
US20160256391A1 (en) 2016-09-08
LT2865391T (lt) 2017-11-27
HK1208351A1 (en) 2016-03-04
CN105744957B (zh) 2019-07-02
JP6461945B2 (ja) 2019-01-30
EP3272361A1 (de) 2018-01-24
EP3272361B1 (de) 2019-11-20
ES2771227T3 (es) 2020-07-06
DK3272361T3 (da) 2020-01-27
ES2648367T3 (es) 2018-01-02
PT2865391T (pt) 2017-12-22
JP6869941B2 (ja) 2021-05-12
EA036982B1 (ru) 2021-01-22
US20200276128A1 (en) 2020-09-03
PT3272361T (pt) 2020-01-21
PL3272361T3 (pl) 2020-04-30
WO2015059023A1 (de) 2015-04-30
LT3272361T (lt) 2020-01-10
EA201690793A1 (ru) 2016-08-31
EP2865391B1 (de) 2017-09-20
NO2865391T3 (pl) 2018-02-17

Similar Documents

Publication Publication Date Title
PT2865391T (pt) Processo para a produção de uma composição farmacêutica liofilizada com um conteúdo de mitomicina c
ZA201405323B (en) New pyrrole compounds ,a process for their preparation and pharmaceutical compositions containing them
IL235826A (en) Diazaspirocycloalkanes and thenaspirocycloalkanes and their preparation
EP2961764A4 (en) PROCESS FOR THE PRODUCTION OF TUBULYSINES
IL243742A0 (en) New indolizine compounds, a process for their preparation and pharmaceutical preparations containing them
PL2897468T3 (pl) Zaawansowane formowanie gum do żucia
PL3046839T3 (pl) Urządzenie do produkcji jednostek opakowań
IL240214A0 (en) A process for the preparation of enantiomerically enriched 3-aminopiperidine
IL241287A0 (en) Processes for the preparation of subfervir
EP2998395A4 (en) METHOD FOR OBTAINING COMPOSITION CONTAINING LACTASE
SG11201601477VA (en) Pharmaceutical composition
IL239697A0 (en) Process for the preparation of a fluorolacton derivative
SG11201501567QA (en) Method for producing 7-octenal
PL3089593T3 (pl) Zaawansowane formowanie gum do żucia
SG11201505385VA (en) Pharmaceutical composition in the form of a tabletand a method for producing same
PL2978321T3 (pl) Sposób wytwarzania herbacianych produktów
PL2996486T3 (pl) Sposób otrzymywania kompozycji stewii
PL3033946T3 (pl) Sposób wytwarzania czekolady i czekolada wytworzona tym sposobem
IL244365A0 (en) pharmaceutical preparation
GB201607411D0 (en) Process for making confections
IL234526A (en) METHOD FOR PRODUCING DIETHINE TETRACARBOXIMIDES
IL244646B (en) Process for preparing 5-fluoro-1-alkyl-3-fluoroalkyl-1h-pyrazole-4-carbaldehyde
PL2862891T3 (pl) Sposób wytwarzania produktów syntetycznych
IL239993A0 (en) Process for preparing 5-fluoro-1-methyl-3-difluoromethyl-h1-pyrazole-4-carbaldehyde
PL2732811T3 (pl) Proces otrzymywania kompozycji liofilizowanej